Close

Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the treatment of short bowel syndrome (SBS).

More Articles ...

Subscribe to our Newsletter
captcha 
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok